

Technical Data Sheet

Purified Rat Anti-Human IL-3

Product Information

Material Number:	554672
Size:	0.5 mg
Concentration:	0.5 mg/ml
Clone:	BVD8-3G11
Immunogen:	Recombinant Human IL-3
Isotype:	Rat IgG1
Reactivity:	QC Testing: Human
Storage Buffer:	Aqueous buffered solution containing ≤0.09% sodium azide.

Description

The BVD8-3G11 antibody reacts with human interleukin-3 (IL-3). The immunogen used to generate the BVD8-3G11 hybridoma was yeast-expressed recombinant human IL-3. This is a neutralizing antibody.

Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Store undiluted at 4° C.

Application Notes

Application

ELISA Capture	Routinely Tested
Western blot	Tested During Development
Neutralization	Tested During Development

Recommended Assay Procedure:

ELISA Capture: The purified BVD8-3G11 antibody (Cat. No. 554672) is useful as a capture antibody in a sandwich ELISA for measuring human IL-3 protein levels. Purified BVD8-3G11 antibody can be paired with the biotinylated BVD3-1F9 antibody (Cat. #554674) as the detecting antibody, with recombinant human IL-3 (Cat. No. 554604) as the standard. This purified capture antibody should be pretitrated in the range of 1 - 4 µg/ml to determine its optimal concentration for ELISA. To obtain linear standard curves, doubling dilutions of human IL-3 ranging from ~2,000 to 15 pg/ml should be used. For specific methodology, please visit our web site, www.bdbiosciences.com, and go to the protocols section or the chapter on ELISA in the Immune Function Handbook.

Note: This ELISA pair is recommended primarily for measuring cytokine from experimental cell culture systems. These ELISA reagents are not recommended for assay of serum samples. For testing human IL-3 in complex biological fluids such as serum or plasma, our BD OptEIA™ Human IL-3 ELISA Set (Cat. No. 555228) is recommended.

WB: The BVD8-3G11 antibody has been found useful for western blotting. A concentration of 1-5 µg/ml (in conjunction with the AKP-conjugated goat anti-rat Igs has been found to enable visualization of ≤ 100 ng/lane of recombinant IL-3 (e.g., Cat. No. 554604), under reducing conditions.

Neutralization: The BVD8-3G11 antibody (Cat. No. 554671) is useful for neutralization of human IL-3 bioactivity.

Suggested Companion Products

Catalog Number	Name	Size	Clone
554674	Biotin Rat Anti-Human IL-3	0.5 mg	BVD3-1F9
554604	Recombinant Human IL-3	10 µg	(none)
554671	Purified NA/LE Mouse Anti-Human IL-3	0.5 mg	BVD8-3G11

BD Biosciences

www.bdbiosciences.com

United States 877.232.8995 Canada 888.259.0187 Europe 32.53.720.550 Japan 0120.8555.90 Asia Pacific 65.6861.0633 Latin America/Caribbean 55.11.5185.9995

For country-specific contact information, visit www.bdbiosciences.com/how_to_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2007 BD



Product Notices

1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

References

Abrams J. Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies. In: Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W, ed. *Current Protocols in Immunology*. New York: John Wiley and Sons; 1995:6.20-6.21.(Clone-specific: ELISA)

Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. *Immunol Rev*. 1992; 127:5-24.(Clone-specific: ELISA, Neutralization)

Abrams JS, Silver J, Van Dyke R, Gleich G. Eosinophil-active cytokines in human disease: development and use of monoclonal antibodies to IL-3, IL-5, GM-CSF. In: Kay A and Gleich G, ed. *Eosinophils in Allergy and Inflammation*. 1994:133-157.(Clone-specific: ELISA, Neutralization)

Kaushansky K, Shoemaker SG, Broudy VC. Structure-function relationships of interleukin-3. An analysis based on the function and binding characteristics of a series of interspecies chimera of gibbon and murine interleukin-3. *J Clin Invest*. 1992; 90(5):1879-1888.(Clone-specific: ELISA)